View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsSelectimmune Pharma 배당 및 자사주 매입배당 기준 점검 0/6Selectimmune Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 26Selectimmune Pharma AB (publ) to Report Q1, 2024 Results on Nov 16, 2023Selectimmune Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 16, 2023공시 • Nov 25Selectimmune Pharma AB (publ) Elects Magnus Nylén as New Member of BoardSelectimmune Pharma AB (publ) announced that at its AGM held on November 23, 2022, the shareholders elected Magnus Nylén as new member of board.공시 • Nov 17+ 1 more updateSelectimmune Pharma AB (publ) to Report Q2, 2023 Results on Feb 23, 2023Selectimmune Pharma AB (publ) announced that they will report Q2, 2023 results on Feb 23, 2023Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Acting CEO, Chief Medical Officer & Board Member Gabriela Godaly was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Nov 15Selectimmune Pharma Has Successfully Completed Preparations to Start A Controlled Clinical Trial in Patients with Bladder Pain SyndromeSelectImmune Pharma has successfully completed preparations to start a controlled clinical trial in patients with bladder pain syndrome (severe pain in the bladder). They can now announce that the study has started and the first patient has been included in the study. The patients must be treated with the drug Kineret, which is an Interleukin1 (IL-1) receptor antagonist (IL-1RA). Patients with bladder pain syndrome have severe pain of unknown cause. Many different treatments have been tried without lasting positive effects. The development of new, more precise drugs has been hampered by the fact that the cause of the pain is unknown. Treatment with IL1RA "off-label" has previously shown positive results in the clinic. Kineret is an IL-1 receptor antagonist that neutralizes the biological activity of the two proinflammatory cytokines IL-1 a and IL-1 b. In the previously treated patients, the pain was reduced and the quality of life increased in this severely disabled patient group. Several patients were able to return to a more normal life. The placebo-controlled study is important to evaluate the treatment effect with greater precision. The study will include a larger number of patients and clinical centers, to address the treatment effect. Research has previously shown that pain is greatly reduced by IL-1RA treatment, even in an animal model. The study will initially include two centers in Sweden, which have extensive experience with this particular patient group. The company has established the study organization in Sweden, received permission from the Swedish Medicines Agency and the Ethical Review Authority and gained access to placebos through an agreement with Sobi (Swedish Orphan Biovitrum). The possibility of treating this patient group is of great medical interest.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Board Member & CMO Gabriela Godaly was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Apr 27Selectimmune Pharma AB (publ) Appoints Gabriela Godaly as Acting CEOSelectimmune Pharma AB (publ) announced that Gabriela Godaly will take the role as acting CEO of SelectImmune Pharma until a new permanent CEO has been appointed. She was appointed Chief Medical Officer of SelectImmune Pharma in 2020 and has served on the Board of Directors since 2019.공시 • Apr 26Selectimmune Pharma AB (publ) Receives Approval to Conduct A Placebo-Controlled Clinical Study of Bladder PainSelectimmune Pharma AB (publ) announced that the Swedish Medical Products Agency (Läkemedelsverket) has approved the application to conduct a placebo-controlled clinical study using IL1-RA for the treatment of Bladder Pain Syndrome. Bladder pain syndrome is a highly painful chronic condition that severely impairs the quality of life of affected patients. Numerous therapeutic approaches have been tested, but currently, no specific therapies are available. Regular painkillers, or even morphine fails to provide adequate symptom relief and even after surgical removal of damaged parts of the bladder, the pain often returns. Company has recently reported positive treatment effects in this patient group, using the IL1-a and ß receptor antagonist (IL1-RA) anakinra, reducing patient symptoms and increasing quality of life. The study also reported positive long-term effects, in patients who continue treatment. SelectImmune Pharma is now proceeding with a randomized, placebo-controlled study of IL1-RA in patients with bladder pain syndrome. The company has received clinical trial authorization from the Swedish Medical Products Agency (Läkemedelsverket). The study is planned to involve several clinical sites.공시 • Mar 30Selectimmune Pharma AB to Conduct Clinical Trials in Cystitis and Bladder Pain SyndromeSelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi) to buy Kineret (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome. Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation and infection in animal models of cystitis and SelectImmune Pharma is now pursuing clinical trials to further assess the clinical efficacy in these areas. Kineret (anakinra) is a trademark of Sobi, who markets the drug for various inflammatory conditions, whereas SelectImmune Pharma's patents cover the use of anakinra for the treatment of cystitis and bladder pain syndrome specifically. The agreement defines that SelectImmune Pharma will conduct clinical trials in these areas with Sobi as the provider of drug and placebo. The parties have the intention to discuss a potential commercialization agreement for the indications protected by SelectImmune Pharma's patent rights.공시 • Mar 28Selectimmune Pharma AB (publ) Announces Resignation of Ann Gidner as CEOSelectImmune Pharma AB's CEO Ann Gidner will leave SelectImmune Pharma, having accepted an offer from a non-competing Life-Science company. Ann Gidner will remain in the CEO role during the notice period of one month. The board has initiated the recruitment of a new CEO for the company.공시 • Feb 25+ 3 more updatesSelectimmune Pharma AB (publ) to Report Q1, 2023 Results on Nov 16, 2022Selectimmune Pharma AB (publ) announced that they will report Q1, 2023 results on Nov 16, 2022공시 • Feb 02SelectImmune Pharma AB Files Important Patent Application for Acute PyelonephritisSelectImmune Pharma AB has filed for patent protection over a range of new agents that show surprising levels of activity in treatment of pyelonephritis. This new patent application adds to SelectImmune Pharma's expanding range of intellectual property rights in the pharmaceutical sector, specifically for treating bacterial infections. Acute pyelonephritis or kidney infection, is a severe and common form of urinary tract infection, caused by bacteria that directly infect the kidneys. In about 30% of adults with acute pyelonephritis, bacteria invade the blood stream, causing urosepsis and without appropriate treatment, mortality is high. Acute pyelonephritis is also common in childhood, and may cause long-term problems by damaging renal tissue. Following extensive research at Lund University into new treatment options for acute pyelonephritis, efficient new approaches have now been identified and the therapeutic effects confirmed in animal models, strengthening the commitment to develop these substances for future clinical use.분석 기사 • Jul 21We're Interested To See How Selectimmune Pharma (NGM:SELECT B) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Mar 24Selectimmune Pharma (NGM:SELECT B) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is New 90 Day High Low • Jan 28New 90-day high: kr16.30The company is up 24% from its price of kr13.12 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.Is New 90 Day High Low • Dec 23New 90-day high: kr15.60The company is up 5.0% from its price of kr14.90 on 23 September 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 5.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: kr12.28The company is down 9.0% from its price of kr13.46 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.공시 • Aug 14Selectimmune Pharma AB (publ) announced that it has received SEK 40 million in fundingSelectimmune Pharma AB (publ) (NGM:SELECT B) announced private placement of common shares for gross proceeds of SEK 40,000,000 in March 2019.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SELECT B 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SELECT B 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Selectimmune Pharma 배당 수익률 vs 시장SELECT B의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SELECT B)n/a시장 하위 25% (SE)1.8%시장 상위 25% (SE)4.2%업계 평균 (Pharmaceuticals)2.7%분석가 예측 (SELECT B) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SELECT B 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SELECT B 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SELECT B 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: SELECT B 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YSE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/08/11 04:41종가2023/08/08 00:00수익2023/03/31연간 수익2022/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Selectimmune Pharma AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 26Selectimmune Pharma AB (publ) to Report Q1, 2024 Results on Nov 16, 2023Selectimmune Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 16, 2023
공시 • Nov 25Selectimmune Pharma AB (publ) Elects Magnus Nylén as New Member of BoardSelectimmune Pharma AB (publ) announced that at its AGM held on November 23, 2022, the shareholders elected Magnus Nylén as new member of board.
공시 • Nov 17+ 1 more updateSelectimmune Pharma AB (publ) to Report Q2, 2023 Results on Feb 23, 2023Selectimmune Pharma AB (publ) announced that they will report Q2, 2023 results on Feb 23, 2023
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Acting CEO, Chief Medical Officer & Board Member Gabriela Godaly was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Nov 15Selectimmune Pharma Has Successfully Completed Preparations to Start A Controlled Clinical Trial in Patients with Bladder Pain SyndromeSelectImmune Pharma has successfully completed preparations to start a controlled clinical trial in patients with bladder pain syndrome (severe pain in the bladder). They can now announce that the study has started and the first patient has been included in the study. The patients must be treated with the drug Kineret, which is an Interleukin1 (IL-1) receptor antagonist (IL-1RA). Patients with bladder pain syndrome have severe pain of unknown cause. Many different treatments have been tried without lasting positive effects. The development of new, more precise drugs has been hampered by the fact that the cause of the pain is unknown. Treatment with IL1RA "off-label" has previously shown positive results in the clinic. Kineret is an IL-1 receptor antagonist that neutralizes the biological activity of the two proinflammatory cytokines IL-1 a and IL-1 b. In the previously treated patients, the pain was reduced and the quality of life increased in this severely disabled patient group. Several patients were able to return to a more normal life. The placebo-controlled study is important to evaluate the treatment effect with greater precision. The study will include a larger number of patients and clinical centers, to address the treatment effect. Research has previously shown that pain is greatly reduced by IL-1RA treatment, even in an animal model. The study will initially include two centers in Sweden, which have extensive experience with this particular patient group. The company has established the study organization in Sweden, received permission from the Swedish Medicines Agency and the Ethical Review Authority and gained access to placebos through an agreement with Sobi (Swedish Orphan Biovitrum). The possibility of treating this patient group is of great medical interest.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Board Member & CMO Gabriela Godaly was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Apr 27Selectimmune Pharma AB (publ) Appoints Gabriela Godaly as Acting CEOSelectimmune Pharma AB (publ) announced that Gabriela Godaly will take the role as acting CEO of SelectImmune Pharma until a new permanent CEO has been appointed. She was appointed Chief Medical Officer of SelectImmune Pharma in 2020 and has served on the Board of Directors since 2019.
공시 • Apr 26Selectimmune Pharma AB (publ) Receives Approval to Conduct A Placebo-Controlled Clinical Study of Bladder PainSelectimmune Pharma AB (publ) announced that the Swedish Medical Products Agency (Läkemedelsverket) has approved the application to conduct a placebo-controlled clinical study using IL1-RA for the treatment of Bladder Pain Syndrome. Bladder pain syndrome is a highly painful chronic condition that severely impairs the quality of life of affected patients. Numerous therapeutic approaches have been tested, but currently, no specific therapies are available. Regular painkillers, or even morphine fails to provide adequate symptom relief and even after surgical removal of damaged parts of the bladder, the pain often returns. Company has recently reported positive treatment effects in this patient group, using the IL1-a and ß receptor antagonist (IL1-RA) anakinra, reducing patient symptoms and increasing quality of life. The study also reported positive long-term effects, in patients who continue treatment. SelectImmune Pharma is now proceeding with a randomized, placebo-controlled study of IL1-RA in patients with bladder pain syndrome. The company has received clinical trial authorization from the Swedish Medical Products Agency (Läkemedelsverket). The study is planned to involve several clinical sites.
공시 • Mar 30Selectimmune Pharma AB to Conduct Clinical Trials in Cystitis and Bladder Pain SyndromeSelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi) to buy Kineret (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome. Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation and infection in animal models of cystitis and SelectImmune Pharma is now pursuing clinical trials to further assess the clinical efficacy in these areas. Kineret (anakinra) is a trademark of Sobi, who markets the drug for various inflammatory conditions, whereas SelectImmune Pharma's patents cover the use of anakinra for the treatment of cystitis and bladder pain syndrome specifically. The agreement defines that SelectImmune Pharma will conduct clinical trials in these areas with Sobi as the provider of drug and placebo. The parties have the intention to discuss a potential commercialization agreement for the indications protected by SelectImmune Pharma's patent rights.
공시 • Mar 28Selectimmune Pharma AB (publ) Announces Resignation of Ann Gidner as CEOSelectImmune Pharma AB's CEO Ann Gidner will leave SelectImmune Pharma, having accepted an offer from a non-competing Life-Science company. Ann Gidner will remain in the CEO role during the notice period of one month. The board has initiated the recruitment of a new CEO for the company.
공시 • Feb 25+ 3 more updatesSelectimmune Pharma AB (publ) to Report Q1, 2023 Results on Nov 16, 2022Selectimmune Pharma AB (publ) announced that they will report Q1, 2023 results on Nov 16, 2022
공시 • Feb 02SelectImmune Pharma AB Files Important Patent Application for Acute PyelonephritisSelectImmune Pharma AB has filed for patent protection over a range of new agents that show surprising levels of activity in treatment of pyelonephritis. This new patent application adds to SelectImmune Pharma's expanding range of intellectual property rights in the pharmaceutical sector, specifically for treating bacterial infections. Acute pyelonephritis or kidney infection, is a severe and common form of urinary tract infection, caused by bacteria that directly infect the kidneys. In about 30% of adults with acute pyelonephritis, bacteria invade the blood stream, causing urosepsis and without appropriate treatment, mortality is high. Acute pyelonephritis is also common in childhood, and may cause long-term problems by damaging renal tissue. Following extensive research at Lund University into new treatment options for acute pyelonephritis, efficient new approaches have now been identified and the therapeutic effects confirmed in animal models, strengthening the commitment to develop these substances for future clinical use.
분석 기사 • Jul 21We're Interested To See How Selectimmune Pharma (NGM:SELECT B) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Mar 24Selectimmune Pharma (NGM:SELECT B) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Is New 90 Day High Low • Jan 28New 90-day high: kr16.30The company is up 24% from its price of kr13.12 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Dec 23New 90-day high: kr15.60The company is up 5.0% from its price of kr14.90 on 23 September 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 5.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: kr12.28The company is down 9.0% from its price of kr13.46 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
공시 • Aug 14Selectimmune Pharma AB (publ) announced that it has received SEK 40 million in fundingSelectimmune Pharma AB (publ) (NGM:SELECT B) announced private placement of common shares for gross proceeds of SEK 40,000,000 in March 2019.